DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
First World Cord Blood Day on Nov. 15 to Highlight Cord Blood Uses, Stem Cell Research
The inaugural World Cord Blood Day on Nov. 15 this year will educate parents and healthcare professionals about the current uses for cord blood transplants, a non-controversial source of stem cells which have the ability to treat more than 80 life-threatening diseases, including sickle cell anemia.
To date, more than 35,000 umbilical cord blood transplants have been performed worldwide since 1988. In the emerging field of regenerative medicine, this approach holds great promise in treating autism, diabetes, stroke and many others. The procedure has also been performed in patients with thalassemia, lymphoma, and leukemia, among others. But umbilical cord blood is still thrown away as medical waste after most births across the world.
Related Content
-
news & eventsBig Jump in Success for Sickle Cell TransplantsDoubling the dose of total-body irradiat...
-
education & researchVaccinations after hematopoietic cell transplantHematopoietic cell transplant recipients...
-
education & researchCognitive behavioral therapy in patients with sickle cell diseaseIntroduction: Sickle cell disease (SCD) ...
-
news & eventsGBT expands sickle cell disease pipeline with worldwide licensing agreement for inclacumab for the treatment of vaso...Global Blood Therapeutics, Inc...
-
news & eventsIronwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disea...Ironwood Pharmaceuticals, Inc., a commer...
-
news & eventsStatement on NHLBI Decision to Pause the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Si...bluebird bio, Inc. suspended its clinica...
-
news & eventsNew Guidelines for Managing Sickle Cell Disease Presented at ACP Internal Medicine MeetingNew guidelines for therapeutic strategie...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.